Announcements
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
- Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
- Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
- Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
- Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
- Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
- Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
- Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
More ▼
Key statistics
On Tuesday, Ovid Therapeutics Inc (1OT:FRA) closed at 3.08, -16.30% below its 52-week high of 3.68, set on Sep 18, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.08 |
---|---|
High | 3.08 |
Low | 3.08 |
Bid | 2.84 |
Offer | 2.90 |
Previous close | 2.86 |
Average volume | 0.00 |
---|---|
Shares outstanding | 70.71m |
Free float | 59.40m |
P/E (TTM) | -- |
Market cap | 236.17m USD |
EPS (TTM) | -0.7415 USD |
Data delayed at least 15 minutes, as of Apr 30 2024 07:11 BST.
More ▼